VistaGen Therapeutics Other Current Assets

VistaGen Therapeutics Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:

The assets grouped under other current assets are most commonly:

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

VistaGen Therapeutics Other Current Assets Related Terms

Thank you for viewing the detailed overview of VistaGen Therapeutics's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

VistaGen Therapeutics Business Description

Industry

Healthcare » Biotechnology NAICS : 325412 SIC : 2834

Comparable Companies

NAS:CLVS NYSE:ZYME XKRX:078160 XKRX:321550 NAS:RLYB NAS:VSTM OSL:ULTI NAS:XERS NAS:KRON NAS:STRO

Traded in Other Exchanges

N/A

Address

343 Allerton Avenue, South San Francisco, CA, USA, 94080

Website

https://www.vistagen.com

VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.

Executives

Saxe Jon S	director	FIRST HORIZON PHARMACEUTICAL CORP 660 HEMBREE PKWY STE 106 ROSWELL GA 30076
Dotson Jerrold Duane	officer: VP, CFO AND SECRETARY	5 CENTERPOINTE DRIVE SUITE 400 LAKE OSWEGO OR 97035
Singh Shawn	director, officer: CHIEF EXECUTIVE OFFICER	C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Snodgrass H. Ralph	director, officer: PRES./CHIEF SCIENTIFIC OFFICER	384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Smith Mark Alan	officer: CHIEF MEDICAL OFFICER	343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Mcpartland Mark A.	officer: VP CORPORATE DEVELOPMENT	C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Gin Jerry B	director	343 ALLERTON AVE SOUTH SAN FRANCISCO CA 94080
Underdown Brian J.	director	C/O LUMIRA CAPITAL INVESTMENT MANAGEMENT 141 ADELAIDE ST. WEST, SUITE 770 TORONTO ONTARIO CANADA M5H 3L5 A6 00000
Cunningham Ann Michelle	director	255 N CALDWELL CIRCLE DOWNINGTOWN PA 19335
Rice A. Franklin	officer: VP CORPORATE DEVELOPMENT	384 OYSTER POINT BLVD. SUITE 8 SOUTH SAN FRANCISCO CA 94080
Bonfiglio Gregory A.	director	384 OYSTER POINT BOULEVARD, NO. 8 SOUTH SAN FRANCISCO CA 94080
Platinum Long Term Growth Vii, Llc	10 percent owner	152 WEST 57TH STREET 4TH FLOOR NEW YORK NY 10019
Cato Holding Co	10 percent owner	4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Cato Allen Easley	10 percent owner	4364 SOUTH ALSTON AVENUE DURHAM NC 27713
Jones Stephanie	director, 10 percent owner, officer: PRESIDENT	13834 W. HOYT ROAD RATHDRUM ID 83858